Frontier IP Group PLC Exscientia rare disease drug discovery collaboration with Rallybio

Frontier IP Group PLC (LON:FIPP), a specialist in commercialising university intellectual property, today noted the following announcement from portfolio company Exscientia, a world leader in artificial intelligence drug discovery, that it has entered into a drug discovery collaboration with Rallybio.

Rallybio is a US-based drug development company aiming to transform the lives of patients with rare diseases.

Exscientia’s other partnerships include collaborations with Celgene, GSK, Roche, Sanofi, GT Apeiron and Evotec. Frontier IP currently holds a 3.25 per cent stake in the Company.

Exscientia statement in full:

EXSCIENTIA ENTERS BROAD RARE DISEASE DRUG DISCOVERY COLLABORATION WITH RALLYBIO

Joint venture will initiate drug discovery programs targeting rare diseases using AI

Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered into a collaboration with Rallybio, a U.S.-based drug development company, which aims to transform lives of patients with rare diseases. The collaboration will combine Exscientia’s AI drug discovery platform with Rallybio’s expertise in rare disease drug development to accelerate the discovery of small molecule drug therapeutics for undisclosed rare disease indications.

It is estimated that there are between 7,000 and 8,000 rare diseases, which affect 25 to 30 million Americans and 30 to 40 million European Union citizens. These diseases pose unique challenges to the healthcare systems around the world because they require specific medical expertise and significant drug research, diagnostic and screening capabilities in order to treat these patients.

Alongside the team of world-class scientists from Rallybio, Exscientia will apply its cutting-edge, Centaur Chemist™, AI drug discovery platform to design pre-clinical drug candidates for the joint venture, RE Ventures, owned equally by Exscientia and Rallybio. The financial details of the collaboration are not disclosed.

“There is a huge potential for artificial intelligence to revolutionise and democratise rare disease drug discovery. AI can fast track, simplify and lower the price of research and we are thrilled to be partnering with Rallybio to achieve this. The future of drug discovery in rare diseases is to be able to address the need for precision engineered drugs at scale and our collaboration with Rallybio is the first step in this direction,” said Andrew Hopkins, CEO of Exscientia.

“Our joint venture brings together Exscientia’s industry-leading AI drug discovery capabilities with Rallybio’s expertise in rare disease drug development,” said Steve Uden, Chief Operating Officer of Rallybio. “We believe this collaboration will accelerate the development of life-transforming therapies for patients suffering from severe and rare disorders.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Frontier IP Group Plc

    More articles like this

    Frontier IP Group Plc

    Animal Lovers and Zoonotic Diseases: 5 Things to Know

    Zoonotic diseases, or zoonoses, are on the rise. That may first bring to mind exotic diseases like Ebola, but the reality is that many zoonotic infections happen closer to home, often during everyday activities. In 2018, we saw

    Frontier IP Group Plc

    AI-based initiatives catalyzing immunotherapy in 2018

    Artificial intelligence (AI) has been dynamically changing the field of drug discovery in several areas, including immunotherapy, oncotherapy, neurological disease, and many more. Described here is an ensemble of the initiatives in place to advance the field of immunotherapy research.

    Frontier IP Group Plc

    Frontier IP Group Plc appoint N+1 Singer as sole broker

    Frontier IP Group PLC (LON:FIPP), a specialist in commercialising university intellectual property, today announced the appointment of Nplus1 Singer Advisory LLP as the Group’s sole broker with immediate effect. Allenby Capital Limited remains the Group’s Nominated Adviser.

    Frontier IP Group Plc

    Britain’s university spinout sector is thriving

    They are among Britain’s greatest national treasures and a powerful engine of ideas and innovation for the nation’s booming technology industry. But how good are UK universities at commercialising the research and expertise which springs from their laboratories

    Frontier IP Group Plc

    Role of Artificial Intelligence in changing the future healthcare

    The major driving force behind the revolution inpatient care is technology. Nowadays, ground-breaking healthcare apps on mobile phones and wearable devices are giving some autonomy to the patients, by increasing their involvement in healthcare, as well as, in

    Frontier IP Group Plc

    Exscientia CEO explains how AI is transforming drug discovery

    In recent decades a strange confluence has formed in the pharmaceutical industry. A range of powerful technologies have brought enormous new capabilities to the sector, productivity has been simultaneously declining. Deloitte’s Centre for Health Solutions estimates that projected returns on investment in pharma

    Frontier IP Group Plc

    How technology is revolutionising the healthcare industry

    A technology revolution is transforming the healthcare industry, changing everything from how patients are diagnosed and treated to our battle against some of the world’s most serious diseases. It’s a revolution fuelled by new sources of healthcare data

    Frontier IP Group Plc

    Artificial Intelligence will Revolutionise Drug Discovery

    New technologies are making their way into the healthcare industry and healthcare providers are already experimenting with advances such as smart pill technology, 3D-printed medication, and mobile apps. But probably the biggest potential lies in artificial intelligence (AI). For